Conferences
ASCO GU 2024: Disparities in Prostate Cancer Mortality and Clinical Trial Availability Across Vulnerable Populations
January 26, 2024
ASCO GU 2024: Differences in Genomic, Transcriptomic, and Immune Landscape of Prostate Cancer Based on Site of Metastasis
January 26, 2024
ASCO GU 2024: Phase 1b/2 Study of Pembrolizumab Plus Belzutifan and Belzutifan Alone in Patients with Docetaxel-treated mCRPC: KEYNOTE-365 Cohort J
January 26, 2024
ASCO GU 2024: Real-World Treatment Patterns for Patients with High-Risk Biochemically Recurrent Nonmetastatic Castration-Sensitive Prostate Cancer
January 26, 2024
ASCO GU 2024: Stockholm3 Validation in a Multi-Ethnic Cohort for Prostate Cancer (SEPTA) Detection: A Multicentered, Prospective Trial
January 26, 2024
ASCO GU 2024: Survival and Fracture Risk with Radium-223 Therapy in mCRPC: A Real-World Analysis
January 26, 2024
ASCO GU 2024: Real-world Analyses of Mortality Risk After ADT Initiation in Black vs White Patients with Prostate Cancer
January 26, 2024